BioNTech SE annual operating margin
2017
2018
2019
2020
2021
2022
2023
2024
2025
BioNTech SE Operating Margin Growth & History (BNTX)
BioNTech SE's operating margin was −48.95% for fiscal 2025.
View full BioNTech SE company overviewBioNTech SE annual operating margin history
| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −48.95% | −1.18 pp |
| 2024 | 2024-12-31 | −47.77% | −65.85 pp |
| 2023 | 2023-12-31 | 18.08% | −54.96 pp |
| 2022 | 2022-12-31 | 73.03% | −7.51 pp |
| 2021 | 2021-12-31 | 80.54% | +97.62 pp |
| 2020 | 2020-12-31 | −17.08% | +150.04 pp |
| 2019 | 2019-12-31 | −167.13% | −124.91 pp |
| 2018 | 2018-12-31 | −42.21% | +57.27 pp |
| 2017 | 2017-12-31 | −99.48% | — |
BioNTech SE quarterly operating margin
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −888.92% | −707.94 pp |
| Q1 2026 | 2026-03-31 | −568.33% | — |
| Q4 2025 | 2025-12-31 | −30.91% | — |
| Q3 2025 | 2025-09-30 | 43.05% | — |
| Q2 2025 | 2025-06-30 | −180.98% | — |
BioNTech SE operating margin trends
Over the last five fiscal years, BioNTech SE's operating margin decreased from −17.08% to −48.95%, a change of −31.87 percentage points. The latest reported quarter, Q2 2026, shows −888.92%.
About the metric
What operating margin means
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
Calculation and source
How operating margin is calculated
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BioNTech SE source filings ↗Community posts
BioNTech reports longer survival in exploratory lung-cancer trial stage
BioNTech ($BNTX) and OncoC4 reported updated results for gotistobart in previously treated advanced squamous non-small cell lung cancer. Median overall survival reached 18.5 months versus 10 months with docetaxel in the non-pivotal first st ...
